Immunotherapies

News

First-in-class hay fever immunotherapy backed for NHS use

A once-daily tablet that can help people suffering from hay fever caused by tree pollen, Alk-Abelló's Itulazax, has been recommended for NHS use.

R&D

The future of fertility and the vaginal microbiome

As societies have modernised, fertility rates have declined substantially.

News

Takeda wagers up to $2.2bn on AC Immune Alzheimer’s shot

Takeda has made a strong play for a stake in the Alzheimer’s disease market, paying $100 million upfront for an option on AC Immune’s amyloid-targeting immunotherapy.

Oncology

The gut microbiome: the next breakthrough in cancer?

Ben Hargreaves discovers how research has emerged outlining how the gut microbiome plays a crucial role in patients’ response to cancer treatments.

Oncology

Partner Content

2nd Next Generation RNA Therapeutics Summit

Bringing Next Generation RNA Therapies to Patients Fast

Views & Analysis

ASCO highlights: the next generation of cancer therapy

For the last two years, the American Society of Clinical Oncology (ASCO) conference has been a reminder that even when COVID dominates headlines, amazing advances are still being made in ca